| Autor: |
Lia K; Vestre Viken, Bærum Hospital, Department of Oncology, Gjettum, Norway; Faculty of Medicine, University of Oslo. kjerli@vestreviken.no., Jørgensen RRK; Clinical Cancer Research Centre, Aalborg University Hospital, Department of Hematology, Denmark; Aalborg University, Department of Clinical Medicine, Denmark., L Wold B; Oslo University Hospital, Department of Oncology., Fluge Ø; Haukeland University Hospital, Department of Oncology, Bergen., Fagerli UM; St. Olavs Hospital, Department of Oncology, Trondheim., Bersvendsen H; University Hospital of North Norway, Department of Oncology, Tromsø., Bø IB; Stavanger University Hospital, Department of Hematology., Bhargava S; Cancer Registry of Norway, Majorstuen, Oslo, Norway; Akershus University Hospital, Department of Oncology, Lørenskog., Fosså A; Oslo University Hospital, Department of Oncology, Norway; KG Jebsen Centre for B-cell Malignancies, University of Oslo, Oslo. |
| Abstrakt: |
Elderly Hodgkin lymphoma (HL) patients are poorly characterized and under-represented in studies. In this national population- based study, we investigated cause-specific survival using competing-risk analysis in elderly HL patients compared to the normal population. Patients ≥60 years of age diagnosed between 2000-2015 were identified by the Cancer Registry of Norway, and records were reviewed in detail and compared to data from the Norwegian Cause of Death Registry for patients and cancer-free controls. Of 492 patients, 81 (17%) were ineligible for treatment directed specifically towards HL, mostly because of an underlying other lymphoma entity, whereas 74 (15%) and 337 (69%) were treated with palliative or curative intent, respectively. Median overall survival in patients ineligible for assessment of HL-directed therapies was 0.5 years (95% Confidence Interval [CI]: 0.4-0.6), and for palliatively and curatively treated patients 0.8 (0.4-1.2) and 9.1 (7.5-10.7) years, respectively. After correction of discrepancies in registry data, with 359 deaths, 108 (30%) died of HL, the most common cause of death. In curatively treated patients, treatment-related mortality was 6.5% and the risk difference of dying from HL compared to controls was 28% (95% CI: 23-33%) after ten years. These numbers indicate disease control in a majority of elderly patients eligible for curative treatment, compared to risk differences for death from HL of 59% (48-71%) and 42% (31-53%) after ten years in the palliative and ineligible groups, respectively. There was an increased risk of dying from hematologic malignancies other than HL in all groups, but not from other competing causes of death, showing no excess mortality from long-term treatment complications. |
